Human CYP4F12 genetic polymorphism: Identification and functional characterization of seven variant allozymes

Equipe d'accueil 2679, Faculté de Médecine de Lille, Pôle Recherche, Lille, France.
Biochemical Pharmacology (Impact Factor: 5.01). 12/2004; 68(12):2417-25. DOI: 10.1016/j.bcp.2004.08.025
Source: PubMed


The human cytochrome CYP4F12 has been shown to be metabolically active toward inflammatory mediators and exogenous compounds such as antihistaminic drugs. We recently identified a genetic polymorphism within the promoter region, associated with a decreased level of enzyme expression. In the present study, we report the further identification of single nucleotide polymorphisms in the coding sequence of the CYP4F12 gene. A polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) analysis of DNA samples from 53 unrelated French Caucasians, allowed the identification of ten mutations, comprising seven missense mutations, 31C>T (Leu11Phe), 38C>T (Pro13Leu), 47C>T (Met16Thr), 4759G>A (Asp76Asn), 4801G>A (Val90Leu), 8896C>T (Arg188Cys) and 23545G>A (Gly522Ser). Their functional impact toward ebastine hydroxylation was evaluated using heterologous expression in Saccharomyces cerevisiae cells of site-directed mutated cDNA variants. Five out seven variants did not exhibit any significant difference in CYP4F12 catalytic activity, whereas two variants, Val90Ile and Arg188Cys, displayed significant changes in their Michaelis-Menten (Km, Vm) parameters. These data on CYP4F12 genetic polymorphism provide tools for further studies of association with pathological processes involving an inflammatory component and with variations in anti-histaminic drug response.

11 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: H1 antihistamines are widely used in the treatment of allergic disorders. The CNS depressant and antimuscarinic effects of the first generation compounds limited their use in allergic disorders, and the second generation compounds were developed to reduce or eliminate these effects. However, the use of the first second generation H1 antihistamines, terfenadine and astemizole, under certain circumstances, was associated with adverse cardiac effects, which were occasionally fatal and they were withdrawn from the market. This review examines the pharmacokinetics of the second generation antihistamines and the impact of the pharmacokinetic properties on their efficacy and safety, particularly with regard to their effects on the central nervous and cardiovascular systems and their potential for interactions with concomitantly administered drugs and dietary components.
    No preview · Article · Sep 2005 · Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cytochromes P450 (P450s or CYPs) constitute a superfamily of heme-containing monooxygenases and have been shown to play a major role in both xenobiotic and endogenous metabolism. Thanks to the Human Genome Project, the current list of human CYPs should be exhaustive and so far 57 P450 encoding genes have been identified. To date, fif-teen of them, generally called "orphans" cytochromes P450, which were mainly identified by homology research between the sequences of known P450s and genomic sequences or ESTs (Expressed Sequence Tags) databases, are not fully char-acterized. However, tissue distribution, catalytic properties and physiological functions of these "novel P450s" are being analysed and partial results are already available for some of them, including CYP2 (CYP2A13, CYP2R1, CYP2S1, CYP2U1 and CYP2W1), CYP3 (CYP3A43) and CYP4 (CYP4A22, CYP4F12, CYP4F22, CYP4V2, CYP4X1, CYP4Z1) family members. In this review, we present some of the current data characterizing these P450s and discuss their potential involvement in xenobiotic toxicity and carcinogenesis, as well as their physiological relevance in pathology susceptibility.
    No preview · Article · Jul 2006 · Current Genomics
  • [Show abstract] [Hide abstract]
    ABSTRACT: The cytochrome P450 4F (CYP4F) subfamily has over the last few years come to be recognized for its dual role in modulating the concentrations of eicosanoids during inflammation as well as in the metabolism of clinically significant drugs. The first CYP4F was identified because it catalyzed the hydroxylation of leukotriene B(4) (LTB(4)) and since then many additional members of this subfamily have been documented for their distinct catalytic roles and functional significance. Recent evidence emerging in relation to the temporal change of CYP4F expression in response to injury and infection supports an important function for these isozymes in curtailing inflammation. Their tissue-dependent expression, isoform-based catalytic competence and unique response to the external stimuli imply a critical role for them to regulate organ-specific functions. From this standpoint variations in relative CYP4F levels in humans may have direct influence on the metabolic outcome through their ability to generate and/or degrade bioactive eicosanoids or therapeutic agents. This review covers the enzymatic characteristics and regulatory properties of human and rodent CYP4F isoforms and their physiological relevance to major pathways in eicosanoid and drug metabolism.
    No preview · Article · Jan 2007 · Pharmacology [?] Therapeutics
Show more